These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
359 related articles for article (PubMed ID: 35063115)
1. Cost-effectiveness of universal screening for chronic hepatitis B virus infection in China: an economic evaluation. Su S; Wong WC; Zou Z; Cheng DD; Ong JJ; Chan P; Ji F; Yuen MF; Zhuang G; Seto WK; Zhang L Lancet Glob Health; 2022 Feb; 10(2):e278-e287. PubMed ID: 35063115 [TBL] [Abstract][Full Text] [Related]
2. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation. Shepherd J; Jones J; Takeda A; Davidson P; Price A Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047 [TBL] [Abstract][Full Text] [Related]
3. Universal screening and treatment towards the elimination of chronic hepatitis C in China: an economic evaluation. Fang K; Wang HL; Lin Y; Zheng L; Li S; Wu J Public Health; 2024 Mar; 228():186-193. PubMed ID: 38387115 [TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of expanded antiviral treatment for chronic hepatitis B virus infection in China: an economic evaluation. Zhang S; Wang C; Liu B; Lu QB; Shang J; Zhou Y; Jia J; Xu X; Rao H; Han B; Zhao T; Chen L; Xie M; Cui J; Du J; Zeng J; Huang N; Liu Y; Zhang L; Zhuang H; Cui F Lancet Reg Health West Pac; 2023 Jun; 35():100738. PubMed ID: 37424693 [TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of community-based screening and treatment for chronic hepatitis B in The Gambia: an economic modelling analysis. Nayagam S; Conteh L; Sicuri E; Shimakawa Y; Suso P; Tamba S; Njie R; Njai H; Lemoine M; Hallett TB; Thursz M Lancet Glob Health; 2016 Aug; 4(8):e568-78. PubMed ID: 27443782 [TBL] [Abstract][Full Text] [Related]
6. Domestic HPV vaccine price and economic returns for cervical cancer prevention in China: a cost-effectiveness analysis. Zou Z; Fairley CK; Ong JJ; Hocking J; Canfell K; Ma X; Chow EPF; Xu X; Zhang L; Zhuang G Lancet Glob Health; 2020 Oct; 8(10):e1335-e1344. PubMed ID: 32971056 [TBL] [Abstract][Full Text] [Related]
7. The cost-effectiveness of universal hepatitis B screening for reaching WHO diagnosis targets in Australia by 2030. Xiao Y; Hellard ME; Thompson AJ; Seaman C; Howell J; Scott N Med J Aust; 2023 Mar; 218(4):168-173. PubMed ID: 36596568 [TBL] [Abstract][Full Text] [Related]
8. Screening and early treatment of migrants for chronic hepatitis B virus infection is cost-effective. Veldhuijzen IK; Toy M; Hahné SJ; De Wit GA; Schalm SW; de Man RA; Richardus JH Gastroenterology; 2010 Feb; 138(2):522-30. PubMed ID: 19879275 [TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of screening and vaccinating Asian and Pacific Islander adults for hepatitis B. Hutton DW; Tan D; So SK; Brandeau ML Ann Intern Med; 2007 Oct; 147(7):460-9. PubMed ID: 17909207 [TBL] [Abstract][Full Text] [Related]
10. Assessing the cost-effectiveness of hepatitis C screening strategies in France. Deuffic-Burban S; Huneau A; Verleene A; Brouard C; Pillonel J; Le Strat Y; Cossais S; Roudot-Thoraval F; Canva V; Mathurin P; Dhumeaux D; Yazdanpanah Y J Hepatol; 2018 Oct; 69(4):785-792. PubMed ID: 30227916 [TBL] [Abstract][Full Text] [Related]
11. Cost effectiveness of screening immigrants for hepatitis B. Wong WW; Woo G; Jenny Heathcote E; Krahn M Liver Int; 2011 Sep; 31(8):1179-90. PubMed ID: 21745300 [TBL] [Abstract][Full Text] [Related]
12. Estimated Cost-effectiveness of Endoscopic Screening for Upper Gastrointestinal Tract Cancer in High-Risk Areas in China. Xia R; Zeng H; Liu W; Xie L; Shen M; Li P; Li H; Wei W; Chen W; Zhuang G JAMA Netw Open; 2021 Aug; 4(8):e2121403. PubMed ID: 34402889 [TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of couple-based immunization strategy to prevent mother-to-child transmission of hepatitis B virus in China: A decision-analytic Markov model. Jing W; Liu J; Wu Y; Ma Q; Liu M EClinicalMedicine; 2020 Feb; 19():100264. PubMed ID: 32055793 [TBL] [Abstract][Full Text] [Related]
14. Universal Hepatitis B Antibody Screening and Vaccination in Pregnancy: A Cost-Effectiveness Analysis. Prabhu M; Susich MK; Packer CH; Hersch AR; Riley LE; Caughey AB Obstet Gynecol; 2022 Mar; 139(3):357-367. PubMed ID: 35115449 [TBL] [Abstract][Full Text] [Related]
15. Impact of the national hepatitis B immunization program in China: a modeling study. Liu Z; Li M; Hutton DW; Wagner AL; Yao Y; Zhu W; Cao L; Tang S; Pan J; Wang Y; Zhao Q; Ren H; Wang Y; Wang W Infect Dis Poverty; 2022 Oct; 11(1):106. PubMed ID: 36221140 [TBL] [Abstract][Full Text] [Related]
16. Impact and Cost-Effectiveness of Biomedical Interventions on Adult Hepatitis B Elimination in China: A Mathematical Modelling Study. Wang X; Du Z; Wang Y; Wang J; Huang S; Wang Y; Gu J; Deng W; Gilmour S; Li J; Hao Y J Epidemiol Glob Health; 2023 Sep; 13(3):517-527. PubMed ID: 37349664 [TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness analysis of a hepatitis B vaccination catch-up program among children in Shandong Province, China. Jia Y; Li L; Cui F; Zhang D; Zhang G; Wang F; Gong X; Zheng H; Wu Z; Miao N; Sun X; Zhang L; Lv J; Yang F Hum Vaccin Immunother; 2014; 10(10):2983-91. PubMed ID: 25483678 [TBL] [Abstract][Full Text] [Related]
18. Strategies for the prevention of perinatal hepatitis B transmission in a marginalized population on the Thailand-Myanmar border: a cost-effectiveness analysis. Devine A; Harvey R; Min AM; Gilder MET; Paw MK; Kang J; Watts I; Hanboonkunupakarn B; Nosten F; McGready R BMC Infect Dis; 2017 Aug; 17(1):552. PubMed ID: 28793866 [TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of risk-stratified endoscopic screening for esophageal cancer in high-risk areas of China: a modeling study. Xia R; Li H; Shi J; Liu W; Cao M; Sun D; He S; Yu Y; Li N; Lei L; Zhuang G; Chen W Gastrointest Endosc; 2022 Feb; 95(2):225-235.e20. PubMed ID: 34418461 [TBL] [Abstract][Full Text] [Related]
20. Cost-Effectiveness of Hepatitis B Mass Screening and Management in High-Prevalent Rural China: A Model Study From 2020 to 2049. Xu X; Wu C; Jiang L; Peng C; Pan L; Zhang X; Shen W; Chen L; Lou Z; Xu K; Li L; Dong Y; Ruan B Int J Health Policy Manag; 2022 Oct; 11(10):2115-2123. PubMed ID: 34664496 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]